Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial

Journal of Nephrology

Volumn 20, Issue 6, 2007, Pages 646-655

  Maione, Ausilia ^a   Nicolucci, Antonio ^a   Craig, Jonathan C ^b,c   Tognoni, Giovanni ^a   Moschetta, Antonio ^a,d   Palasciano, Giuseppe ^d   Pugliese, Giuseppe ^e   Procaccini, Deni A ^f   Gesualdo, Loreto ^g   Pellegrini, Fabio ^a   Strippoli, Giovanni F M ^a,b,c   Valentini, Miriam ^a   Pirozzoli, Celeste ^a   Di Nardo, Barbara ^a   Ferrari, Sonia ^a   Piaggione, Marco ^a   Di Lallo, Rosalia ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

^c University of Sydney   (Australia)

^d UNIVERSITY OF BARI   (Italy)

^e POLICLINICO UMBERTO I   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Cardiovascular risk factors; Combined therapy; Microalbuminuria; Urinary albumin creatinine ratio

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; ITALY; LONGITUDINAL STUDIES; MALE; MYOCARDIAL INFARCTION; OBESITY; RENIN-ANGIOTENSIN SYSTEM; SMOKING;

EID: 39449104268     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Yuyun MF, Adler AI, Wareham NJ. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens 2005; 14: 271-6.
2. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, Kusek JW, Byrd-Holt D, Narayan KM, Herman WH, Jones CP, Salive M, Agodoa LY. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-59.
3. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE; Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26.
4. Atkins RC, Polkinghorne KR, Briganti EM, Shaw JE, Zimmet PZ, Chadban SJ. Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney Int Suppl 2004; 92: S22-4.
5. Casiglia E, Zanette G, Mazza A, Donadon V, Donada C, Pizziol A, Tikhonoff V, Palatini P, Pessina AC. Cardiovascular mortality in non-insulin-dependent diabetes mellitus: a controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. Eur J Epidemiol 2000; 16: 677-84.
6. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736-41.
7. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992; 41: 731-5.
8. Ostgren CJ, Lindblad U, Melander A, Rastam L. Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 2002; 25: 1297-302
9. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004; 159: 284-93.
10. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 3081-91.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella J; for National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
12. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 2006; 29 (suppl 1): S4-42.
13. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (suppl 1): S1-290.
14. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-153.
15. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thorn SM; for BHS Guidelines Working Party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-40.
16. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828-39.
17. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
18. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-24.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
21. Erstad S, Poore R. Ankle-brachial index test. WebMD Web site. http://www.webmd.com/heart-disease/Ankle-brachial-index-test. Updated November 3, 2005. Accessed October 18, 2007.
22. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study: a novel design for intervention trials. Blood Press 1992; 1: 113-9.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.